Outcomes of patients not achieving primary endpoint from an ibalizumab Phase III trial

被引：0
|
作者：
DeJesus, E. [1 ]
Emu, B. [2 ]
Weinheimer, S. [3 ]
Cohen, Z. [4 ]
Cash, B. [5 ]
Lewis, S. [3 ]
机构：
[1] Orlando Immunol Ctr, Infect Dis, Orlando, FL USA
[2] Yale Sch Med, Infect Dis, New Haven, CT USA
[3] TaiMed Biol, HIV, Irvine, CA USA
[4] Theratechnologies, HIV, Montreal, PQ, Canada
[5] Syneos Hlth, HIV, Somerset, NJ USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P064
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of docetaxel duration on clinical outcomes: Results from the phase III trial CLEOPATRA
    Miles, D.
    Fung, A.
    Yoo, B.
    Knott, A.
    Heeson, S.
    Portera, C.
    Swain, S.
    CANCER RESEARCH, 2016, 76
  • [22] Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials
    Djulbegovic, Benjamin
    Kumar, Ambuj
    Miladinovic, Branko
    Mhaskar, Asmita
    Reljic, Tea
    Galeb, Sanja
    Mhaskar, Rahul
    Iztok, Hozo
    Tu, Dongsheng
    Stanton, Heather
    Booth, Christopher M.
    Meyer, Ralph M.
    BLOOD, 2011, 118 (21) : 237 - 237
  • [23] The impact of blinded endpoint review on the incidence of primary short-term outcomes in the SIFT trial
    Partlett, Christopher
    Linsell, Louise
    Hewer, Oliver
    Juszczak, Ed
    Dorling, Jon
    TRIALS, 2017, 18
  • [24] Associations between prognosis and primary endpoint selection in phase III oncology trials in the United States
    Uemura, Nariaki
    Ono, Shunsuke
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
    Xu, B.
    Zhang, Q.
    Sun, T.
    Li, W.
    Teng, Y.
    Hu, X.
    Bondarenko, I.
    Adamchuk, H.
    Li, Y.
    Shan, B.
    Cheng, J.
    Peng, T.
    Wang, X.
    Chen, Y.
    Jiang, W.
    Liu, S.
    Zhang, X.
    Liu, E.
    Luk, A.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Phase III randomized controlled trial of adjuvant chemoimmunotherapy in patients with resected primary lung cancer
    Kimura, H.
    Matsui, Y.
    Nakajima, T.
    Iizasa, T.
    Ishikawa, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] A SEQUENTIAL PHASE-II/III TRIAL FOR BINARY OUTCOMES
    STORER, BE
    STATISTICS IN MEDICINE, 1990, 9 (03) : 229 - 235
  • [28] MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2014, 15 (03): : 278 - 279
  • [29] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Denize, Thomas
    Farah, Subrina
    Cimadamore, Alessia
    Flaifel, Abdallah
    Walton, Emily
    Sticco-Ivins, Maura A.
    Labaki, Chris
    Braun, David A.
    Sun, Maxine
    Wang, Evelyn
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
  • [30] Acalabrutinib Phase III Study ELEVATE-TN achieves Primary Endpoint in Interim Analysis of Patients with untreated chronic lymphocytic Leukemia
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 420 - 420
12345